Leqembi 관련 새로운 임상 데이터 발표, 알츠하이머 치료에 획기적 진전

Company

Biogen, Eisai

Category

임상시험/파이프라인

Drug (API)

Kisunla (donanemab-azbt)

Indication

Alzheimer's disease

Official Announcement

https://www.globenewswire.com/news-release/2024/07/30/2921454/0/en/New-Clinical-Data-Demonstrates-Three-Years-of-Continuous-Treatment-with-Dual-Acting-LEQEMBI-lecanemab-irmb-Continues-to-Significantly-Benefit-Early-Alzheimer-s-Disease-Patients-Pre.html

BioSpace

https://www.biospace.com/drug-development/new-leqembi-data-illuminate-longer-term-effects-tau-reduction

Firstword

https://firstwordpharma.com/story/5880760

Fierce Group

https://www.fiercepharma.com/pharma/eisai-biogen-show-leqembi-provides-added-benefits-over-time

Release Date

2024/08/05

TA

Neurology

Type

Conference

Approval DB

Class

Clinical DB

Licensing DB

Licensing DB (1) (Article DB)에 관계됨

Partnership DB

Target

Upload Date

3 more properties

한글종합기사

Official Announcement

BioPharma Dive

BioSpace

Firstword

Fierce Group